Skip to main content

Mark Knight


Authored Items
Initial Choice of TKI in Patients with CML Probably Not Important
Mark Knight
February 2013 Vol 6, No 1, Special Issue in Leukemia, Oncology
Can Prognostic Factors Guide the Treatment of DLBCL?
Mark Knight
February 2013 Vol 6, No 1, Special Issue
Newly Discovered Genes in AML Can Identify Likely Response to Therapies
Mark Knight
February 2013 Vol 6, No 1, Special Issue
Molecular and Cytogenetic Assessments Infrequently Performed in Patients with CML Receiving First-Line Imatinib
Mark Knight
February 2013 Vol 6, No 1, Special Issue in Leukemia, Oncology
Head-to-Head Comparison: Exenatide Outperforms Glimepiride in Controlling Glycemic Levels after Failing Metformin Therapy
Mark Knight
August 2012, Vol 5, No 5, Special Issue ADA 2012 Highlights
Head-to-Head Comparison: Exenatide Outperforms Glimepiride in Controlling Glycemic Levels after Failing Metformin Therapy
Mark Knight
Value-Based Care in Cardiometabolic Health August 2012, Vol 1, No 2
High OOP Costs for Medicare Patients with Cancer
Mark Knight
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective
Last modified: August 29, 2012